The FDA has approved avacopan as an adjunctive treatment for adults with severe active ANCA-associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis ...

Patients who receive avacopan for antineutrophil cytoplasmic antibody-associated vasculitis demonstrate fewer infections and ...

ANCA Vasculitis Disorder: Type: Body Parts Affected: Common Symptoms: Granulomatosis with polyangiitis (GPA), formerly known as Wegener's granulomatosis Small and medium blood vessels - Sinuses ...

The FDA approved the oral complement 5a receptor inhibitor avacopan (Tavneos) for the treatment of severe, active antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, drugmaker ...

ChemoCentryx shares more than tripled on Tuesday after the firm, in conjunction with Vifor Fresenius Medical Care Renal Pharma, announced positive topline data from its late-stage trial of ...

The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis.In this randomized, controlled trial, we assigned ...

The approval was based on data from the phase 3 ADVOCATE trial, which evaluated Tavneos in 330 adults with newly diagnosed or relapsed ANCA-associated vasculitis. The Food and Drug Administration ...

The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (eg, ANCA vasculitis) are a heterogeneous group of rare, life-threatening, immune-mediated disorders that are characterized ...

The ANCA test can also show if the treatment you take for vasculitis is working. And your doctor can use it to predict whether your symptoms might come back after treatment, which is called a relapse.

However, estimates of infection rates in ANCA-associated vasculitis have been wide, ranging from only 6% to as high as 67%, and most often have been limited to cases involving hospitalization.

Findings in Context. This study brings clarity on how to best manage patients with ANCA-associated vasculitis, Robert Hylland, MD, an assistant clinical professor of rheumatology at Michigan State ...

Dr. Kevin Deane discusses a recent meta-analysis assessing the efficacy of glucocorticoid therapy in preventing relapse in ANCA-positive vasculitis.